These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4941731)

  • 1. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.
    Bertler A; Jeppsson PG; Nordgren L; Rosengren E
    Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 4. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 7. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J; Sharpe D; Curzon G
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract]   [Full Text] [Related]  

  • 8. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 9. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa: alterations in behavior.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Clin Pharmacol Ther; 1971; 12(2):383-96. PubMed ID: 4930867
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of L-DOPA in the therapy of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G
    Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinsonism-dementia of Guam: treatment with L-dopa.
    Schnur JA; Chase TN; Brody JA
    Neurology; 1971 Dec; 21(12):1236-42. PubMed ID: 4257247
    [No Abstract]   [Full Text] [Related]  

  • 15. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
    Parkes JD; Baxter RC; Curzon G; Knill-Jones RP; Knott PJ; Marsden CD; Tattersall R; Vollum D
    Lancet; 1971 May; 1(7709):1083-6. PubMed ID: 4102620
    [No Abstract]   [Full Text] [Related]  

  • 17. L-dopa in idiopathic parkinsonism.
    Calne DB; Stern GM; Spiers AS; Laurence DR
    Lancet; 1969 Nov; 2(7628):973-6. PubMed ID: 4186975
    [No Abstract]   [Full Text] [Related]  

  • 18. Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa.
    Wilk S; Mones R
    J Neurochem; 1971 Sep; 18(9):1771-3. PubMed ID: 5571114
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of L-dopa in Parkinson's disease.
    Godwin-Austen RB; Tomlinson EB; Frears CC; Kok HW
    Lancet; 1969 Jul; 2(7613):165-8. PubMed ID: 4183130
    [No Abstract]   [Full Text] [Related]  

  • 20. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.
    Godwin-Austen RB
    J Neurol Neurosurg Psychiatry; 1971 Jun; 34(3):219-23. PubMed ID: 5571307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.